Carregant...

Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications

BACKGROUND: The MDS-IWG and NCCN currently endorse both FAB and WHO classifications of MDS and AML, thus allowing patients with 20–30 % bone marrow blasts (AML20–30, formerly MDS-RAEB-t) to be categorised and treated as either MDS or AML. In addition, an artificial distinction between AML20–30 and A...

Descripció completa

Guardat en:

Dades bibliogràfiques
Publicat a:	J Hematol Oncol
Autors principals:	Pleyer, Lisa, Burgstaller, Sonja, Stauder, Reinhard, Girschikofsky, Michael, Sill, Heinz, Schlick, Konstantin, Thaler, Josef, Halter, Britta, Machherndl-Spandl, Sigrid, Zebisch, Armin, Pichler, Angelika, Pfeilstöcker, Michael, Autzinger, Eva-Maria, Lang, Alois, Geissler, Klaus, Voskova, Daniela, Geissler, Dietmar, Sperr, Wolfgang R., Hojas, Sabine, Rogulj, Inga M., Andel, Johannes, Greil, Richard
Format:	Artigo
Idioma:	Inglês
Publicat:	BioMed Central 2016
Matèries:	Research
Accés en línia:	https://ncbi.nlm.nih.gov/pmc/articles/PMC4833933/ https://ncbi.nlm.nih.gov/pubmed/27084507 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-016-0263-4
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications

Ítems similars